Mobile Clinical Trial Units
The COVID-19 pandemic created a unique challenge for clinical trials, both in the need to rapidly accelerate new coronavirus studies while pausing non-COVID related research. With clinical space at a premium and normal capacity impeded by the pandemic, mobile clinical trial units offer an innovative solution to facilitate these important studies.
On site or out in the community, mobile units provide an agile, flexible and compliant space to support decentralised and hybrid clinical trials.
Please get in touch with our team to discuss the options we have to help.
We understand that every clinical need can be unique. This is why our approach is tailored to meet your specific requirements.
What research will be carried out on the unit?
What clinical requirements should the facility meet?
What is the scale of the study?
When is the research unit required?
Will the unit remain static or regularly relocate?
World first trial of new cancer screening test
The world’s largest trial of a revolutionary new blood test, the NHS-Galleri Trial, will be conducted on board EMS mobile healthcare spaces as part of a three year study.
The project will trial the Galleri™ test among 140,000 volunteers in England aged 50-77. Participants will be screened for more than 50 types of cancer – including those that are hard to detect in their early stages, such as head, neck and oesophageal cancers.
Organised by GRAIL Bio UK Ltd in partnership with NHS England, The Cancer Research UK and King’s College London Cancer Prevention Trial Unit. The EMS Group are providing 11 mobile healthcare spaces and recruiting over 120 clinical staff to support the delivery of this world first trial.Find out more
"Scientific research and healthcare studies have been integral in the fight against COVID-19, with clinical trials crucial in developing diagnostics and treatments for the virus. We're so proud to support several healthcare providers with much needed temporary infrastructure to expand their research studies, installing mobile units with minimal footprints to increase capacity on crowded hospital estates."
Clinical trials have enabled the healthcare system to better understand COVID-19 and develop successful treatments and vaccines against it. Guy’s and St Thomas’ NHS Foundation Trust were an integral part of these pioneering studies, ultimately assisting in the successful development of the University of Oxford and AstraZeneca COVID-19 vaccine.
With 7,929 individuals taking part in the Trust's COVID-19 research studies, the hospital needed an innovative solution to rapidly maximise trial space on an already crowded hospital estate. With the most suitable location being a small area away from the main building, our team built and deployed a bespoke mobile unit that would fit the tight space within 3 weeks from project confirmation.
UK’S LARGEST LUNG CANCER SCREENING CLINICAL TRIALEMS Healthcare News
The Yorkshire Lung Screening Trial is the UK's largest randomised trial of Lung Cancer Screening, and will test the effectiveness of community-based lung health checks. The clinical trial is part of a multi-million-pound investment by Yorkshire Cancer Research in ground-breaking initiatives that will improve lung cancer outcomes and increase early diagnosis in the region. Dr Kathryn Scott, Chief Executive at Yorkshire Cancer Research, said: “We are delighted to be funding this trial which tackles the biggest health problem currently facing our region. The outcomes of this initiative will be instrumental in influencing how we deliver effective lung diagnosis services in the future, and in ultimately improving patient outcomes."Read the full article
The Yorkshire Lung Screening Trial is the largest randomised trial of Lung Cancer Screening in the UK. The trial tests the effectiveness of community-based lung health checks, inviting those at high risk of developing lung cancer to the mobile unit for screening.
The mobile facility travels throughout the community - providing screening within convenient locations such as supermarket car parks and shopping centres. By improving accessibility, the unit can better reach at risk residents to ultimately detect cancer at an earlier stage and improve patient outcomes. With 6,552 people screened so far, the trial has been extended for a further 18 months and now also screens participants for kidney cancers.